NRSNClinical Trial•prnewswire•September 10, 2025 at 06:30 PM

NeuroSense's Drug Candidate Shows Early Signals of Benefit in Alzheimer's Patient-Derived Neurons

Sentiment:Positive (70)

Summary

(NASDAQ:NRSN) Initial Phase 2 RoAD trial results demonstrate improvements in brain-cell connectivity and health, with a favorable safety profile CAMBRIDGE, Mass., Sept. 10, 2025 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company...

Original Article

Read the full article from the original source for complete details and context.

Read Full Article

Article published on September 10, 2025 by prnewswire